KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt: 2017-2025

Historic Non-Current Debt for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $2.6 billion.

  • Amneal Pharmaceuticals' Non-Current Debt rose 18.29% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 18.29%. This contributed to the annual value of $2.2 billion for FY2024, which is 9.40% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Non-Current Debt is $2.6 billion, which was up 19.57% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Non-Current Debt ranged from a high of $2.7 billion in Q1 2021 and a low of $2.1 billion during Q2 2025.
  • Moreover, its 3-year median value for Non-Current Debt was $2.4 billion (2024), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Non-Current Debt decreased by 14.64% in 2024, and later grew by 18.29% in 2025.
  • Amneal Pharmaceuticals' Non-Current Debt (Quarterly) stood at $2.7 billion in 2021, then declined by 3.29% to $2.6 billion in 2022, then dropped by 7.95% to $2.4 billion in 2023, then fell by 9.40% to $2.2 billion in 2024, then climbed by 18.29% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q3 2025, $2.1 billion for Q2 2025, and $2.2 billion during Q1 2025.